Compare ZYME & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZYME | CASH |
|---|---|---|
| Founded | 2003 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2022 | 1996 |
| Metric | ZYME | CASH |
|---|---|---|
| Price | $22.88 | $91.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | $38.90 | ★ $96.33 |
| AVG Volume (30 Days) | ★ 630.3K | 228.1K |
| Earning Date | 01-01-0001 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.22% |
| EPS Growth | ★ 33.33 | 18.88 |
| EPS | N/A | ★ 1.57 |
| Revenue | $105,965,000.00 | ★ $839,894,000.00 |
| Revenue This Year | $162.82 | $7.56 |
| Revenue Next Year | N/A | $6.02 |
| P/E Ratio | ★ N/A | $57.18 |
| Revenue Growth | ★ 38.87 | 11.29 |
| 52 Week Low | $9.03 | $64.45 |
| 52 Week High | $28.49 | $96.06 |
| Indicator | ZYME | CASH |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 53.25 |
| Support Level | $22.23 | $71.74 |
| Resistance Level | $23.66 | $95.58 |
| Average True Range (ATR) | 1.42 | 2.81 |
| MACD | -0.05 | -0.74 |
| Stochastic Oscillator | 9.06 | 45.07 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.